In a posthoc analysis of the CKVO 90-11 trial, almost 400 patients with stage III CRC were assessed for MSI as well as tumor protein 53 (TP53) mutations in exons 4 to 8 (the majority of mutations were in the DNA binding domain) and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in exons 1 and 2. The gene discussed is KRAS; the disease is colorectal carcinoma.